Search Results for "vol"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for vol. Results 771 to 780 of 1549 total matches.
Sofpironium (Sofdra) for Primary Axillary Hyperhidrosis
The Medical Letter on Drugs and Therapeutics • Aug 19, 2024 (Issue 1709)
retention (2%). ApplicationThe
Medical Letter ® Vol. 66 (1709) August 19, 2024
134
site reactions ...
The FDA has approved a 12.45% gel formulation of the
anticholinergic drug sofpironium (Sofdra – Botanix) for
treatment of primary axillary hyperhidrosis (excessive
underarm sweating) in patients ≥9 years old.
Med Lett Drugs Ther. 2024 Aug 19;66(1709):133-4 doi:10.58347/tml.2024.1709c | Show Introduction Hide Introduction
Drugs for Thyroid Disorders
Treatment Guidelines from The Medical Letter • Aug 01, 2009 (Issue 84)
from The Medical Letter • Vol. 7 (Issue 84) August 2009
with 50-100 mcg/day, but others begin with full ...
Primary hypothyroidism is usually the result of Hashimoto's thyroiditis, thyroidectomy for hyperthyroidism, goiter or cancer, or radioactive iodine therapy for hyperthyroidism.
Drugs for HIV Infection
Treatment Guidelines from The Medical Letter • Feb 01, 2014 (Issue 138)
for HIV Infection
8 Treatment Guidelines from The Medical Letter • Vol. 12 (Issue 138) • February 2014 ...
Antiretroviral therapy is recommended for all HIV-infected
patients, both to reduce the risk of disease
progression and to prevent transmission of the virus to
others. Various guidelines for treatment of HIV infection
are available.
Antibacterial Drugs for Community-Acquired Pneumonia
The Medical Letter on Drugs and Therapeutics • Jan 25, 2021 (Issue 1616)
heart, lung, liver or renal
disease, diabetes, alcoholism, malignancy, or
11
The Medical Letter ® Vol ...
Treatment of community-acquired pneumonia (CAP)
is usually empiric, with selected antibiotic regimens
directed against some of the most common causative
pathogens. Recommended empiric regimens are
listed in Table 2; recommended antibiotic dosages for
treatment of CAP are listed in Tables 3 and 4. Joint
guidelines for treatment of CAP by the American
Thoracic Society and the Infectious Diseases Society of
America (ATS/IDSA) were updated in 2019.
Drugs for Hypothyroidism
The Medical Letter on Drugs and Therapeutics • Feb 20, 2023 (Issue 1670)
) ................... p 27
The Medical Letter ® Vol. 65 (1670) February 20, 2023
Thyroid Function Tests (TFTs ...
Primary hypothyroidism is usually the result of
Hashimoto's (autoimmune) thyroiditis, thyroidectomy,
or radioactive iodine therapy. Treatment of
hypothyroidism with replacement doses of thyroid
hormone is usually lifelong. Levothyroxine (LT4;
synthetic thyroxine; Synthroid, and others) is the drug
of choice.1
Med Lett Drugs Ther. 2023 Feb 20;65(1670):25-9 doi:10.58347/tml.2023.1670a | Show Introduction Hide Introduction
Acetaminophen Safety
The Medical Letter on Drugs and Therapeutics • Oct 28, 2002 (Issue 1142)
Letter, Inc. • 1000 Main Street, New Rochelle, NY 10801 • A Nonprofit Publication
Vol. 44 (W1142A ...
An FDA panel has recommended that stronger warnings about hepatotoxicity be added to the labeling for acetaminophen (www.fda.gov, search "acetaminophen hepatotoxicity").
Nivolumab (Opdivo) for Metastatic Melanoma and Metastatic NSCLC
The Medical Letter on Drugs and Therapeutics • Jun 08, 2015 (Issue 1470)
in 142 patients
86
The Medical Letter ® Vol. 57 (1470) June 8, 2015
Table 1. Some Drugs for Metastatic ...
The FDA has approved nivolumab (Opdivo – BMS),
an IV programmed death receptor-1 (PD-1) blocking
antibody, for treatment of unresectable or metastatic
melanoma that has progressed following treatment
with ipilimumab (and a BRAF inhibitor in patients who
are BRAF V600 mutation positive) and for treatment
of metastatic squamous non-small cell lung cancer
(NSCLC) that has progressed on or after platinum-based
chemotherapy. It is the second PD-1 inhibitor to
be marketed in the US after pembrolizumab (Keytruda),
and the first to be approved for treatment of NSCLC.
Two New Drugs for Skin and Skin Structure Infections
The Medical Letter on Drugs and Therapeutics • Aug 18, 2014 (Issue 1449)
dosage is 10-15 mg/kg q6h.
The Medical Letter ® Vol. 56 (1449) August 18, 2014
to another glycopeptide ...
The FDA has approved two new drugs for treatment
of adults with acute bacterial skin and skin structure
infections caused by susceptible gram-positive
bacteria. Dalbavancin (Dalvance – Durata) is a long-acting
intravenous (IV) lipoglycopeptide antibiotic
similar to telavancin (Vibativ). Tedizolid phosphate
(Sivextro – Cubist) is an IV and oral oxazolidinone
antibacterial drug similar to linezolid (Zyvox). A
third IV antibiotic, oritavancin (Orbactiv), recently
approved by the FDA for the same indication, will be
reviewed in a future...
IV Amisulpride (Barhemsys) for Postoperative Nausea and Vomiting
The Medical Letter on Drugs and Therapeutics • Dec 28, 2020 (Issue 1614)
® Vol. 62 (1614) December 28, 2020
Table 3. Some Drugs for Prevention and Treatment of PONV1
Some ...
The FDA has approved IV amisulpride (Barhemsys –
Acacia), a selective dopamine-2 and -3 (D2/D3) receptor
antagonist, for prevention and treatment of postoperative
nausea and vomiting (PONV) in adults. It is the first
antiemetic to be approved for rescue treatment of
PONV in patients who have symptoms despite receiving
antiemetic prophylaxis. Oral formulations of amisulpride
are available in Europe for treatment of schizophrenia
and acute psychotic episodes.
Two New Pneumococcal Vaccines - Prevnar 20 and Vaxneuvance
The Medical Letter on Drugs and Therapeutics • Nov 29, 2021 (Issue 1638)
. Accessed November 10, 2021.
189
The Medical Letter ® Vol. 63 (1638) November 29, 2021
VACCINES – PCV20 ...
The FDA has licensed two new pneumococcal
conjugate vaccines (PCVs) for prevention of invasive
pneumococcal disease in adults: Prevnar 20 (PCV20;
Pfizer), which contains antigens from 20 serotypes of
pneumococcus, and Vaxneuvance (PCV15; Merck),
which contains antigens from 15 serotypes. Two
other pneumococcal vaccines are available in the
US: Prevnar 13 (PCV13; Pfizer), a 13-valent conjugate
vaccine licensed for use in persons ≥6 weeks old,
and Pneumovax 23 (PPSV23; Merck), a 23-valent
pneumococcal polysaccharide vaccine licensed for
use in persons ≥2 years...